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Background: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and
effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other
disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin
releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial
aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.
Methods/design: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of
PTSD of at least 3 months’ duration, are being enrolled in a parallel-group, double-blind, placebo-controlled,
randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist.
GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial
hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale
(CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may
influence treatment response are measured prior to randomization and after five weeks’ exposure to the study
medication, including: fear conditioning and extinction using psychophysiological measures; variants of
stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD
and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the
fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a
one-month follow-up period to monitor for sustained response and resolution of any adverse effects.
Discussion: Considerable preclinical and human research supports the hypothesis that alterations in central
nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess
the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and
neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms
of PTSD.
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Posttraumatic stress disorder (PTSD) is a chronic and
prevalent anxiety disorder that follows exposure to an over-
whelming traumatic event [1]. The majority of patients with
PTSD also meet criteria for other psychiatric disorders and
experience significant functional impairment [2]. Many also
attempt suicide [3]. Despite its impact on society, there is
only partial understanding of the etiology or pathophysi-
ology of this disorder. Effective pharmacotherapy options
remain limited, with only sertraline and paroxetine
approved by the US Food and Drug Administration (FDA)
for PTSD. Response rates to these selective serotonin re-
uptake inhibitors (SSRIs) rarely exceed 60%, and even fewer
patients (20 to 30%) achieve clinical remission [4]. The In-
stitute of Medicine’s review of treatments for PTSD con-
cluded that there is insufficient evidence to support the use
of any medication for PTSD [5]. Thus, there is a clear need
to develop novel and improved therapeutics for PTSD.
A growing body of literature suggests that stress-related
disorders such as PTSD are associated with chronically
increased activity of central nervous system circuits
that utilize the 41 amino acid peptide neurotransmitter
corticotropin releasing hormone (CRH, also known as
corticotropin releasing factor, CRF). CRH mediates the neu-
roendocrine, immune, autonomic, and behavioral responses
to stress [6]. CRH levels are increased by stress, resulting in
activation of the hypothalamic-pituitary-adrenal (HPA) axis
and increased release of cortisol and other adrenal steroids.
In addition, extrahypothalamic neurons containing CRH
are located throughout the brain, including the prefrontal
and cingulate cortices, central nucleus of the amygdala, bed
nucleus of the stria terminalis, nucleus accumbens, peria-
queductal gray, and brain stem nuclei such as the major
norepinephrine-containing nucleus, the locus ceruleus, and
the serotonin nuclei in the dorsal and median raphe [7].
PTSD has been associated with abnormalities in HPA axis
hormones, both basal and after low-dose dexamethasone
dosing [8].
Increased activity of CRH-containing neurons in
the amygdala activates fear-related behaviors [9], while
neocortical CRH may reduce reward expectation [10].
Intracerebroventricular administration of CRH produces
anxiety-like behaviors in animal models, including fea-
tures particularly relevant to PTSD such as sleep
disturbance, enhanced acoustic startle response, and in-
creased conditioned fear responses. CRH type 1 receptor
(CRHR1) antagonists reverse stress-related behaviors in
preclinical models, including the elevated plus-maze, de-
fensive withdrawal, light/dark transfer, and conditioned
fear paradigms [11]. Animal models of early life stress
have been associated with hyperactivity of CRH neurons,
with chronic activation of CRHR1 in limbic brain re-
gions [12,13]. Mice deficient in CRHR1 display de-
creased anxiety-like behavior and an impaired stressresponse [14]. Startle reactivity in mice depends on re-
ciprocal interactions between CRH and norepinephrine
systems [15]. In PTSD patients, increased cerebrospinal
fluid CRH concentrations were found with single lumbar
puncture sampling [16,17] as well as throughout a 24-
hour period [18]. In addition, PTSD has been associated
with increased psychophysiological responses, such as
startle, skin conductance, and heart rate reactivity [19].
Recent studies using fear conditioning methods have
found that PTSD patients have impaired inhibition of
fear [20] and deficits in fear extinction [21].
Animal models suggest that CRHR1 antagonists may have
therapeutic utility in stress-related disorders, but these
agents have not previously been investigated in patients with
PTSD [22]. Functional activity and in vitro binding assays
indicate that GSK561679 is a potent CRHR1 antagonist.
GSK561679 is an investigational drug and is not currently
FDA-approved for any indication. The most frequently re-
ported adverse event (AE) in prior studies of GSK561679 in
healthy controls and depressed subjects was headache.
Other commonly reported AEs included fatigue, somno-
lence, dizziness, nausea, nasal congestion, upper respiratory
tract infection, influenza and acne. No specific laboratory
abnormalities, vital sign changes, or electrocardiographic
concerns have been identified in humans to date. However,
degenerative changes of the testes were observed in rats,
dogs, and cynomolgus monkeys, though the change was
minimal in nature (that is, reduction in sperm production)
and was reversible after a period of drug withdrawal. Dam-
age to the seminiferous epithelium was also identified. This
concern has led to the exclusion of men from clinical trials
using GSK561679.
This clinical investigation is part of a translational collab-
orative effort supported by the National Institute of Mental
Health (NIMH) National Cooperative Drug Discovery/De-
velopment Groups (NCDDG) program. The NCDDG pro-
gram encourages collaborations between clinical and
preclinical academic researchers and industry with the goals
of developing novel tools for drug development and ‘first in
human, first in patient testing’, as well as facilitating part-
nerships between academia and industry.
In this investigation, we are conducting a four-site
(Emory University, Icahn School of Medicine at Mount
Sinai (MSSM), Baylor College of Medicine (BCM), and
the University of California San Francisco (UCSF)/San
Francisco Veterans Affairs Medical Center (SFVAMC)),
six-week, randomized, double-blind, placebo-controlled,
parallel-arm, fixed dose trial evaluating the efficacy,
safety, and tolerability of GSK561679 in female adult
outpatients with PTSD.
AIMS
The primary aim of this study is to determine the effi-
cacy and safety of GSK561679 in the treatment of
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pre- and post-treatment variables believed to have cli-
nical and pathophysiological importance in PTSD: 1)
fear conditioning and extinction; 2) hormones of the




Women with chronic PTSD of at least moderate severity
are randomized to six weeks of double-blind treatment with
either GSK561679 or placebo in a 1:1 manner. Prior to
randomization, subjects complete assessments of neuro-
psychological function, startle testing, and HPA axis sensi-
tivity. These measures are repeated after five weeks on the
study medication to evaluate potential mediators and mo-
derators of clinical change. DNA for genotyping is also col-
lected. Following the six weeks of treatment, subjects enter
a one month follow-up phase to monitor for safety and
durability of any clinical changes.
The study is being conducted in accord with the latest
version of the Declaration of Helsinki [23]. Each site’s
Institutional Review Board (IRB) approved the study de-
sign, procedures, and recruitment strategies, with Emory
University serving as the lead site (Emory University
IRB, IRB number 00022717; Mount Sinai School of
Medicine IRB, IRB number 04-0900 0001 03; Baylor
College of Medicine IRB, IRB number H-30433 and the
Michael E DeBakey Veterans Affairs Medical Center
Research and Development Program, ID number 12G19.
HBP; University of California San Francisco IRB, and the
San Francisco Veterans Affairs Research and Develop-
ment Committee, IRB number 12-09929). The study is
registered at Clinicaltrials.gov: NCT01018992.
Study participants
Women 18 to 65 years old who meet Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition
(DSM-IV-TR) defined criteria for current PTSD of at
least three months’ duration are eligible. All interested
subjects undergo telephone screening to assess prelimi-
nary eligibility, and potentially eligible subjects are then
scheduled for an in-office screening visit. Subjects are
paid US$50 for each study visit, excluding the screening
visit.
Study sites
The study is being performed at four academic sites in
the United States: Emory University, MSSM, BCM, and
UCSF.
Screening and treatment assessments
The schedule of assessments is presented in Table 1. After
providing written informed consent, study participantsmeet with a staff member for an initial screening interview.
The results of this initial interview are then presented to a
study psychiatrist, who confirms the PTSD diagnosis, evalu-
ates exclusionary psychiatric diagnoses, and clarifies med-
ical history and current treatment. Participants who remain
eligible then complete the Structured Clinical Interview for
DSM-IV (SCID) [24] administered by a trained clinical
interviewer. Demographic data on age, race, ethnicity, edu-
cation level, marital status, employment status, and living
situation are collected using a screening intake form. Family
psychiatric history is collected using a self-report form list-
ing major Axis I diagnoses and death from suicide.
Because many patients with PTSD have experienced
multiple traumas over their lifetime, it is necessary to
identify the ‘index’ trauma, defined as the trauma cur-
rently causing the greatest distress or impairment to the
patient. To identify the index trauma, participants
complete Parts 1 and 2 of the Posttraumatic Diagnostic
Scale (PDS) [25] at the screening visit. Part 1 is a short
checklist of 12 items that identifies potentially trauma-
tizing events the patient has experienced, and Part 2 asks
which of these events has troubled them most in the last
month. After confirmation with the study clinician, the
trauma identified in Part 2 is determined to be the pri-
mary trauma and used as the focus of the Clinician-
Administered PTSD Scale (CAPS) [26], to monitor
PTSD symptom severity and change throughout the
trial. The CAPS is a 17-item scale that assesses each of
the 17 DSM-IV PTSD symptom diagnostic criteria. Each
symptom is scored separately for both its frequency and
intensity. Frequency ratings are made on a 5-point scale
(0 = never; 4 = daily or all the time). Symptom intensity
ratings are made on a 5-point scale (0 = none or no
problem with symptoms; 4 = extreme, incapacitating).
The total CAPS score is the sum of the frequency and
intensity scores for each item. At the screening and
baseline (that is Visit 3) visits, the CAPS is scored separ-
ately for symptoms present for the past week and for the
past month. Subjects must score ≥ 50 for both the past
week and the past month at the screening and baseline
visits to remain eligible for the study. After baseline, the
CAPS is assessed only for the past week of symptoms,
except for the final visit (Visit 11, one month after last
dose of study medicine), when past week and past
month are both scored.
Depressive symptom burden is assessed using the
structured interview guide for the Montgomery-Asberg
Depression Rating Scale (MADRS) [27,28], a 10-item in-
strument assessing symptom severity over the previous
week, in which each item is scored from 0 to 6. Overall
symptom burden and functional status is assessed using
the Clinical Global Impression of Severity (CGI-S) and,
after randomization, the CGI-Improvement (CGI-I) scale
[29]. Self-reported symptoms of PTSD are captured
Table 1 Schedule of events
Screening and pre-randomization assessment Double-blind phase Follow-up
Visit number S1 V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11
Week −1 −1 0 1 2 4 5 5 6 7 10
Day −7 −1 0 7 14 28 35 36 42 49 70
Informed consent X
Demographics/Hollingshead X
Vital signs X X X X X X X X X X X X
Weight X X X X X X
Physical examination X X
12-lead ECG X X X X
SCID-IV X
Dispense study drug and diary X X X X
Screening laboratory tests X
Fecal occult test X
Safety laboratory testing X X X X X X
Pregnancy testing X X X X
Pharmacokinetics X X X X X
Psychiatric measures
CAPS/MADRS/CSSRS/CGI X X X X X X X X
PSS-SR/QIDS-SR X X X X X X X X
CTQ and PDS screen X




Adverse events/Concomitant medications X X X X X X X X X X X X
PRISE X X X X X X
FIBSER X X X X X X
Exploratory aims
Neuroendocrine measures X X X X
Startle testing X X
Neuropsychological testing X X
Genotype X
mRNA X X
Abbreviations: BPI = Brief Pain Inventory; CAPS = Clinician-Administered PTSD Scale; CGI = Clinical Global Impression; CSSRS = Columbia Suicide Severity Rating
Scale; CTQ = Childhood Trauma Questionnaire; ECG = electrocardiogram; FIBSER = Frequency, Intensity and Burden of Side Effects Rating; Hollingshead =
Hollingshead 4 Factors of Social Status Scale; LES = Life Experiences Survey; MADRS =Montgomery-Asberg Depression Rating Scale; PDS = Posttraumatic
Diagnostic Scale; PRISE = Patient Rated Inventory of Side Effects; PSQI = Pittsburgh Sleep Quality Index; PSS-SR = PTSD Symptom Scale Self Report; QIDS-SR = Quick
Inventory of Depressive Symptoms; SCID = Structured Clinical Interview for DSM-IV; SDS = Sheehan Disability Scale.
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[30]. The PSS-SR asks subjects to indicate the frequency
of the 17 DSM-IV symptom criteria items over the past
week, each rated on a 0 to 3 scale. The version of the
PSS-SR used in this trial includes six additional validity
assessment items, which do not contribute to the total
score. Self-reported depression severity is captured using
the Quick Inventory of Depressive Symptoms, Self-
report (QIDS-SR) [31]. The QIDS-SR is a 16-iteminstrument that assesses the severity of depressive symp-
toms present in the past seven days, with each item
scored 0 to 3.
Lifetime history of suicide attempts and suicidal ideation
is assessed at screening using the Columbia Suicide Severity
Rating Scale (C-SSRS) [32]. The C-SSRS is a clinician-
administered measure that assesses the essential informa-
tion regarding suicide (behavior, ideation, lethality and se-
verity) and distinguishes between suicidal occurrences and
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quent administrations of the C-SSRS assess the time period
since the most recent visit. Demographic variables and fam-
ily history of psychiatric illness are collected via self-report
and the Hollingshead Four Factor Index of Social Status
[33]. Childhood trauma history is assessed via the Child-
hood Trauma Questionnaire (CTQ) [34]. Inclusion and ex-
clusion criteria are listed in Table 2.
As part of the screening assessment, participants are
evaluated to ensure adequate physical health and to rule
out medical causes for psychiatric symptoms. This evalu-
ation includes: a medical review of systems, physical
exam, electrocardiogram and laboratory assessments
(comprehensive metabolic panel, complete blood count,
thyroid-stimulating hormone level, pregnancy test, and
urinalysis and urine drug screen).
In preclinical testing, GSK561679 was associated with
gastric mucosal erosions indicative of a local irritancy in
some rat and cynomolgus monkey studies. Thus, partici-
pants who continue to meet eligibility criteria upon
completion of the screening visit are instructed to collect
a stool sample to assess for the presence of occult
gastrointestinal bleeding, which is tested at their next




To better understand the pathophysiology of PTSD, and
to explore potential moderators and mediators of treat-
ment outcomes, four biological measures are assessed
prior to randomization.
1. Psychophysiological testing Psychophysiological test-
ing is performed at Visit 1, prior to randomization, and
repeated at Visit 7, after five weeks of study medication.
Fear-potentiated startle and skin conductance response
are used to assess fear conditioning and extinction, as
well as the subjects’ awareness of reinforcement contin-
gencies in the experiment. The experimental paradigm is
a conditional discrimination model (termed AX+/BX−),
which is specifically designed to test fear inhibition in
addition to fear learning and discrimination between
danger and safety signals [35]. In this paradigm, the rein-
forced conditioned stimulus (CS+) referred to as AX+, is
always paired with the aversive unconditioned stimulus
(US), whereas the non-reinforced conditioned stimulus
(CS−), referred to as BX−, is never paired with the US.
The conditioning phase consists of three blocks of four
trials of each type (AX+, BX−, and noise alone trials).
Fear inhibition is assessed on safety transfer trials that
combine elements of both CSs (known as AB). There
are three AB trials in the transfer test. The extinction
session occurs ten minutes after the fear inhibition testand includes AX and BX trials, but neither is paired with
the US. Extinction consists of six blocks of four trials of
each type.
The US is a 250 ms airblast with an intensity of 80 psi
directed to the larynx as described in similar human fear
conditioning studies [36,37]. The CSs used in the fear
conditioning and extinction sessions are different col-
ored shapes presented on a computer monitor. The star-
tle probe (noise burst) is a 108-dB [A] SPL, 40-ms burst
of broadband noise with a near instantaneous rise time,
delivered 6 seconds after CS onset. In the reinforced tri-
als (CS+), the airblast is delivered 0.5 seconds after the
startle probe and co-terminates with the CS. The stimuli
are presented using SuperLab 3.0 for Windows (Cedrus,
Inc., San Pedro, CA, USA) and synchronized with the
psychophysiological data acquisition using a DIO card
(Measurement- Computing, Inc., Norton, MA, USA).
Psychophysiological data are collected with a Biopac
MP150 (Biopac Systems, Inc., Goleta, CA, USA).
The acoustic startle response (eyeblink component) is
measured via electromyography (EMG) of the right orbi-
cularis oculi muscle. Two 5 mm Ag/AgCl pre-gelled dis-
posable electrodes are positioned approximately 1 cm
under the pupil and 1 cm below the lateral canthus. All
resistances are less than 6 kilo-ohms. EMG activity is ac-
quired at a sampling rate of 1 kHz, amplified and digi-
tized using the EMG module of the Biopac system. The
peak amplitude of the EMG measured between 20 and
200 ms after startle probe onset is used as the measure
of startle magnitude. The skin conductance level (SCL)
is acquired at a sampling rate of 1 kHz using the GSR
module of the Biopac system. Two 5 mm Ag/AgCl dis-
posable electrodes filled with isotonic paste are attached
to the hypothenar surface of the palm of the non-
dominant hand. The average SCL during the three to six
seconds after CS onset will be subtracted from the one
second pre-CS baseline to calculate skin conductance re-
sponse (SCR).
To assess subject awareness and US expectancy during
each experimental session subjects respond on a re-
sponse keypad (SuperLab, Cedrus Corp.) during the
presentation of each trial. During both fear conditioning
and extinction sessions subjects press a button marked
‘+’ if they expect a CS to be followed by the US, a button
marked ‘−’ if they do not expect a CS to be followed by
the US, and a button marked ‘0’ if they are uncertain of
what to expect.
2. Genotyping Whole blood for DNA extraction, and
for DNA and lymphoblast banking at the Rutgers Cell &
DNA Repository (http://www.rucdr.org/), is collected
from every consenting patient at the screening visit.
DNA will be used for genotyping genetic polymor-
phisms, mostly single nucleotide polymorphisms (SNPs),
Table 2 Inclusion and exclusion criteria
Inclusion criteria
1 Female outpatients between 18 and 65 years old.
2 Primary psychiatric diagnosis of DSM-IV defined Posttraumatic Stress
Disorder of at least three months duration.
3 Total CAPS past week and past month scores≥ 50 at the screening
and Visit 3 (randomization) visits.
4 Able to independently understand and provide written informed
consent.
5 A negative urine toxicology.
6 For women of reproductive age, use of an effective birth control
methoda for the duration of the study or abstinence.
7 Subjects who have a history of peptic ulcer disease with known
etiology must provide documentation that effective treatment was
provided with full eradication of ulcers and symptoms.
Exclusion criteria
1 Current participating in another clinical trial in which she is, or will
be, exposed to an investigational or non-investigational drug or
device, or has done so within the month prior to screening.
2 Current evidence or history of significant unstable medical illness or
organic brain impairment, including stroke, central nervous system
tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal,
renal or hepatic impairment that would likely interfere with the
action, absorption, distribution, metabolism, or excretion of
GSK561679.
3 Subjects who in the investigator’s judgment pose a current suicidal
or homicidal risk.
4 Diagnosis of anorexia nervosa or bulimia in the past year.
5 Use of systemic corticosteroids within two weeks of the
Randomization Visit.
6 Treatment with any other psychoactive medication within two
weeks of Visit 1, including all antidepressants, psychoactive herbal
or nutritional treatment (St Johns Wort, SAM-e), lithium, other mood
stabilizers, oral antipsychotics, depot antipsychotics within 12 weeks,
beta blockers, thioridazine, pimozide, opiates, anxiolytics, and
sedatives (with the exception of zolpidem, eszopiclone, and
zaleplon). Also any treatment with any medication that the
investigator judges not acceptable for this study.
7 Current pregnancy or lactation.
8 A positive stool test for occult blood.
9 Subjects who, in the opinion of the investigator, would be
noncompliant with the visit schedule or study procedures (for
example, illiteracy, planned vacations, or planned hospitalizations
during the study).
10 Previous treatment with CRF1 receptor antagonist.
11 Any laboratory abnormality that in the investigator’s judgment is
considered to be clinically significant.
12 Current treatment with exposure-based psychotherapy that targets
PTSD symptoms.
13 Current or planned litigation or other actions related to secondary
gain regarding the traumatic event.
Table 2 Inclusion and exclusion criteria (Continued)
14 Any cardiac condition or ECG evidence that the investigator feels
will predispose the subject to ischemia or arrhythmia.
15 ECG results indicating a QTc > 450 msec at either the Screening or
Randomization Visit unless repeat ECG shows that the parameter
had returned to within normal range by the Randomization Visit.
aAcceptable methods of birth control include: surgical sterility;
postmenopausal status (defined as no menses for at least 12 months); a
double-barrier method (condoms plus diaphragm); hormonal contraceptives
plus single barrier (birth control pills, implants (Norplant) or injections (Depo-
Provera)), intrauterine device (IUD), or abstinence.
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stress-related candidate genes that emerge from previous
human or animal studies, including genes from the HPA
axis, monoaminergic systems, or neurotrophic systems.
The study was not powered to test for genome-wide as-
sociations; however, data from it might be useful in
meta-analyses across studies.
3. Gene expression profiles Whole blood collected in
Tempus blood RNA tubes (Applied Biosystems, Grand
Island, NY, USA) is collected for RNA at Visit 2 prior to
randomization and at Visit 7, after five weeks on the
study medication. Expression of specific candidate tran-
scripts encoding chaperone and co-chaperone proteins
of the glucocorticoid receptor, using real-time PCR as
well as gene-expression microarrays, will be performed.
We will assess the correlation of these gene-expression
patterns with other putative biomarkers (for example,
the dexamethasone suppression test) to evaluate whether
they can be used to predict or mediate change during
treatment.
4. Neuroendocrine evaluation Salivary samples are a
validated means of non-invasively estimating circadian
cortisol rhythms and of monitoring the dexamethasone
suppression response for use as a marker of PTSD. At
Visit 1, subjects are given pre-labeled Salivette collection
tubes (Sarstedt, Rommesldorf, Germany) and instructed
in the sample collection process. On the morning of
Visit 2, one day prior to randomization, participants col-
lect three salivary samples: (1) immediately upon awak-
ening (and prior to eating); (2) 30 minutes after
awakening, and (3) 60 minutes after awakening. Partici-
pants come to the clinic for Visit 2 at 8 am for the
venipuncture collection of plasma cortisol and ACTH
levels. Upon completion of Visit 2, participants are given
two more Salivettes and one pill of dexamethasone
0.5 mg. On the night of Visit 2, participants collect the
fourth salivary sample at 11 pm, followed immediately
by ingestion of the dexamethasone. On the morning of
Visit 3, subjects collect the fifth salivary sample upon
awakening and return to the clinic at 8 am for the post-
dexamethasone venipuncture for plasma cortisol and
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Visits 7 and 8 in order to assess change in the neuroen-
docrine measures after five weeks on study medication.
Due to confounding of HPA measures stemming from
altered circadian rhythms, night-shift workers do not
complete this component of the study.
B. Neuropsychological assessments
We will assess the cognitive and functional ability of
participants at Visit 1, prior to randomization, and again
at Visit 7, after five weeks on study medication.
1. Neuropsychological battery The MATRICS Consen-
sus Cognitive Battery (MCCB), excluding the Social
Cognition assessment portion, is used to assess for
neuropsychological (NP) impairment [38]. This assess-
ment can detect both improvements in NP performance
if any occur, but also unanticipated worsening, if any, be-
cause of the lack of floor effects in the assessment. The
MATRICS Battery includes ten different standard NP
tests, which are administered with standard instructions
and have extensive normative standards available. The
tests include: Category Fluency; Brief Assessment of
Cognition in Schizophrenia Symbol Coding; Trail-
Making Test, Part A; Continuous Performance Test,
Identical Pairs Version; University of Maryland Letter-
Number Span; Wechsler Memory Scale-III Spatial Span;
Hopkins Verbal Learning Test-R; Brief Visual Memory
Test-Revised; and Neuropsychological Assessment Bat-
tery Mazes.
2. Performance based-measures of functional cap-
acity The assessment of functional capacity uses instru-
ments previously developed for use by patients with
schizophrenia: the UCSD performance-based skills as-
sessment (UPSA) [39]. The UPSA-B is an abbreviated
version of the UPSA that involves role-play tasks similar
in complexity to those that a community-dwelling per-
son is likely to encounter and can be administered in ten
minutes. The UPSA-B’s two domains result in a sum-
mary score ranging from 0 to 100.
C. Cross-site calibration
Calibration of clinical, psychophysiological and neuro-
psychological measures was conducted prior to begin-
ning enrollment at each site and periodically through
the trial. The lead investigators for the psychophysio-
logical and neuropsychological components personally
trained each site’s personnel in the testing procedures
and actively monitor the quality of data collection
through the trial. In addition, study administration, con-
duct, and recruitment are addressed in monthly confer-
ence calls involving each site’s principal investigator,
project leads, and associated study staff.Randomization
Randomization occurs at Visit 3. To prevent confounding
of the biological measures by the dexamethasone dose on
the night before Visit 3, baseline laboratory and ECG tests
are conducted the day prior at Visit 2. At Visit 3, upon
completion of the post-dexamethasone venipuncture, par-
ticipants are assessed with the CAPS, MADRS, C-SSRS,
and CGI-S. To be eligible for randomization, participants
have to score ≥ 50 on the CAPS rating for both the past
week and the past month at this visit. At this visit subjects
also complete the PSS-SR, QIDS-SR, the Pittsburgh Sleep
Quality Index (PSQI) [40], Brief Pain Inventory (BPI) [41],
and Patient Rated Inventory of Side Effects (PRISE) [42].
Self-reported functioning is assessed using the Sheehan
Disability Scale (SDS) [43]. To assess the impact of recent
significant life events, participants also complete the Life
Experiences Survey (LES) [44].
Participants who meet all inclusion and no exclusion
criteria are eligible for randomization. Treatment assign-
ment lists, generated using randomized permuted blocks
for each site, are used at each site to ensure equal alloca-
tion across treatment groups across the sites and at any
time during the study. These lists were individually
printed, placed in sealed opaque envelopes by the study
biostatistician, and then delivered directly to the Investi-
gational Drug Pharmacy personnel at each site. When a
participant completes all procedures necessary for
randomization, the study physician at each site notifies
the pharmacy personnel, who assign the patient to the
treatment group indicated on the randomization list.
Protocol treatments
GlaxoSmithKline provided the study medication and
matching placebo at no cost to the study. Bulk-shipped
medication received at the Emory Investigational Drug Ser-
vice is shipped as needed to the other sites’ investigational
pharmacies. Medication throughout the trial is fixed at
350 mg nightly. The medication is formulated as white tab-
lets, in two strengths: 50 mg and 100 mg, dispensed in sep-
arate bottles. Subjects take three of the 100 mg and one of
the 50 mg tablets nightly between 6 and 8 pm, and record
their dosing dates and times in a simple diary.
Pharmacokinetic measures of GSK561679 are assessed
from single sample plasma collections at Visits 4, 5, 6, 9
and 11, and stored at −80°C until analyzed. Each partici-
pant’s pharmacokinetic samples are batch processed
after their study participation is completed; conse-
quently, they will not be used to guide dosing decisions
or identify non-adherent subjects during their study
treatment. Results from the analyses will be unblinded
after finalizing all clinical trial data to identify: 1)
whether any subjects did not take the study medication,
and 2) to evaluate for associations between blood con-
centration and clinical effects.
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Symptom severity ratings are performed at weeks 1, 2, 4,
and 6 post-randomization. At each of these visits, partic-
ipants complete the PSS-SR, and QIDS-SR to assess
PTSD and depressive symptom severity, respectively. A
qualified rater administers the CAPS (for the past week),
MADRS, and C-SSRS and all subjects also meet with a
study psychiatrist for assessment of CGIs, concomitant
medications, and adverse events. Additional self-report
measures repeated at the week 6 post-randomization
visit include the BPI, PSQI, LES and SDS. Vital signs are
assessed at each visit and laboratory testing, particularly
for liver enzyme changes, is conducted throughout the
trial according to the schedule in Table 1. Side effect
burden is assessed through physician inquiry and patient
completion of the PRISE and the Frequency, Intensity,
and Burden of Side Effects Rating (FIBSER) [42].Follow-up period
All participants who complete the six-week treatment
phase or who terminate the trial early will return to the
clinic 7 days (Visit 10) and 1 month (Visit 11) after their
last dose of study medication. At these visits, rating
scales and questionnaires of symptom severity, adverse
events, and changes to concomitant medications are
assessed, as identified in Table 1. Subjects with clinically
significant abnormal laboratory tests or ECG findings at
Visit 9 have those tests repeated at these follow-up visits.
Upon study completion, all participants receive assist-
ance in transitioning to another care provider as clinic-
ally appropriate at the research site (if they choose to do
so) or are referred back to their physician.Major endpoints
The primary outcome is mean change on the CAPS past-
week score between the two treatment arms. Secondary
outcomes include response and remission on the CAPS
past-week score. Response is defined as≥ 50% reduction
from the baseline CAPS total score at the final on-drug
study visit (V9 for completers). Remission is defined as a
CAPS score ≤ 20 at the final on-drug visit.Data management
Case report forms are adaptations of NIMH and
industry-funded clinical trial protocols in PTSD. Study
data is recorded on paper forms and entered into a
password-protected relational database (Microsoft Office
Access 2010, Microsoft, Redmond, WA, USA). A local
area network resident relational database (Microsoft Of-
fice Access 2010, Microsoft, Redmond, WA, USA) serves
as the secure repository for study data. Database man-
agement is performed by the study biostatistician.Data analyses
Primary aim
Primary analysis Our primary statistical analysis plan
will be performed under the intent-to-treat (ITT)
principle that utilizes a likelihood-based, mixed effects
model that assumes any missing data meet the missing
at random (MAR) assumption. Continuous variables will
be fit using SAS PROC MIXED (SAS Institute Inc., Cary,
NC, USA), and categorical data will be fit using the
gllamm add-on to Stata [45]. Prior to model fitting, we
will examine the distributions of the continuous out-
come variables using visual inspection of histograms and
boxplots to identify potential outliers. If variables are
not normally distributed or contain outliers, then log
transformations will be considered or appropriate non-
parametric procedures will be substituted for the ana-
lyses stated. To address the possible increase in Type I
errors due to multiple outcome variables, we have a
priori selected a single outcome measure (CAPS total
for past week) which will maintain the significance level
(α) 0.05 for the primary analysis. For secondary outcome
measures, we will adjust P-values by controlling for the
false discovery rate [46] and report both unadjusted and
adjusted P-values.Assessment of confounders
We expect the randomization procedure to equalize risk
factors across treatment groups; however, we will produce
summary statistics to explore any unexpected differences in
the values of covariates in the treatment groups. While we
do not expect differences in covariates in the treatment
groups, it is likely that the response groups will differ on
some relevant clinical variables (for example, comorbid
conditions). Thus, we will formally assess response group
differences in possible covariates of interest and incorporate
any covariates identified that are considered both statisti-
cally and clinically relevant as additional main effects for
the analyses of response predictors and moderators.Site effects
Our assumption for the analysis plan and power calcula-
tions is that the protocols will be implemented with suf-
ficient consistency to avoid significant site effects in the
results. Given that the randomization will be blocked by
site, there is no reason to believe that the subjects will
have a different a priori probability of response or will
be significantly different from a clinical perspective.
However, we will test for site differences in all outcome
measures with appropriate univariate comparisons to en-
sure that site is not a significant confounder. If there is
evidence of significant site differences in response out-
comes, we will proceed with stratified analyses in place
of the proposed analyses.
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Response rates We will use a mixed effects model for
the binary response data (generalized linear mixed
model or GLMM) where, at each time point, a subject
will be classified as a responder if there is at least 50%
improvement in CAPS compared to the baseline meas-
ure. The factors in the model will be the same as for
testing the primary hypothesis above. This analysis is an
averaged group comparison of time-point specific re-
sponse rates, and thus a patient can change response
categories over time. We anticipate observing a signifi-
cant group-by-time interaction and will perform post
hoc tests by time point to estimate when a significant di-
vergence in response rates occurs.
Depressive symptoms
We will use the same approach as for the primary ana-
lysis of the CAPS as a continuous variable as described
above, except using MADRS as the dependent variable.
Safety and tolerability
We will statistically test the equivalence of various pos-
sible adverse events (for example, headache, insomnia)
from the PRISE and FIBSER using a test of the group ef-
fect in either logistic or Poisson regression models, de-
pending on whether the outcome is a count or a binary
measure. We will also compare time to dropout as well
as first adverse event in both groups using a log-rank
test of Kaplan-Meier curves to determine the possible ef-
fect of adverse events on the course of treatment
response.
Exploratory aims
Effects on treatment on additional measures of change
in PTSD-related symptomatology (which are the PSS-
SR, CGI, and SDS) will be analyzed with a similar ap-
proach as the CAPS. These analyses will be strictly con-
firmatory in nature.
Psychophysiological testing
For the fear-potentiated startle paradigm, the mean star-
tle magnitude for each CS type in each block will be
used to calculate percent change scores with the follow-
ing formula using noise alone (NA) trials as the
reference:
Percent potentiation ¼ 100  CS startle magnitudeð Þ
– NA startle magnitudeð Þ
= NA startle magnitudeð Þ
Discrimination between danger and safety signals will
be calculated as the difference in potentiation between
CS + and CS − trials. Fear inhibition will be assessed as
the difference between the reinforced trials duringconditioning (AX+) and the transfer trials containing el-
ements of CS + and CS − (which are AB trials). Finally,
fear extinction will be measured as the decrease in re-
sponse to the CS + during the extinction session. Given
the assumption of significant individual variation in the
psychophysiological measures, we will perform mixed ef-
fects linear models comparing treatment group for each
fear-potentiated startle measure (conditioning, discrim-
ination, transfer of safety, and extinction) with Block,
Time (baseline versus six weeks) as the within-subjects
factor and Group (GSK561679 versus placebo) as the
between-subjects factor and including a random inter-
cept. The effect of interest will be the group*time inter-
action, indicating a significant difference between groups
in change in startle over time. Skin conductance re-
sponse will be analyzed in a parallel manner. Contin-
gency awareness will be analyzed by comparing US-
expectancy ratings for each CS trial type in a parallel
manner.
Neuroendocrine testing
The difference between plasma cortisol concentrations
obtained pre- and post-dexamethasone will be used to
calculate cortisol suppression (post-pre). Cortisol sup-
pression will then be compared across groups by per-
forming a linear regression of the change in cortisol
level from Day 2 to Day 1 (8 am levels), while control-
ling for Day 1 8 am level as a covariate. Presence of
dexamethasone in the Day 2 sample will confirm that
the participant has taken the drug. Because individual
differences in dexamethasone bioavailability can alter
post-dexamethasone cortisol suppression, plasma dexa-
methasone concentrations will be used as a covariate in
statistical analyses. The difference between salivary corti-
sol peak and trough will be calculated to achieve an esti-
mate of range, which can be compared across groups
using a Wilcoxon rank sum test.
Cognitive function
Using the computer program provided with the
MATRICS battery, we will develop a composite score for
use in the exploratory analyses of the role of neuro-
psychological variables in treatment response. This score
is a standard (that is ‘t’) score, so that changes from
baseline are easily interpretable in terms of their effect
sizes. We will also perform additional exploratory ana-
lyses of those tests in the battery specifically shown to
be sensitive to PTSD in prior studies (Hopkins Verbal
Learning Test and letter-number span).
Moderator analyses
We have a priori specified factors that we expect may
moderate the treatment effect in PTSD subjects [47].
These include, age, type and age of trauma exposure,
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cifically powered to detect these effects, we will analyze
treatment by subgroup interaction effects in these ex-
ploratory analyses in order to provide important infor-
mation for the design of future, more definitive studies.
We will determine significant moderators by specifically
testing the treatment by variable interaction added to
the analysis of the primary outcome. Given the limited
sample size, each possible moderator will be analyzed
separately.
Statistical power/sample size
As this is the first trial of a CRHR1 antagonist in PTSD,
we do not have any pilot data from which to estimate an
effect size. Our sample size calculation of 154 subjects is
based on an effect size of seven CAPS points, consistent
with the observed difference in the study by Davidson
and colleagues of the efficacy of sertraline for PTSD
[48]. We used that study’s effect size and pooled
between-subjects standard deviation, and expected early
termination rates, to construct our power calculation on
the specific test of the treatment group-by-time (two
timepoints, pre and post) interaction effect for a stand-
ard repeated measures analysis of variance [49]. We used
an alpha of 0.05 for all main effects and the interaction,
and calculated that a sample size of 50 completers per
group allows us to detect an interaction effect of this
size with a power of 0.91. With the expected dropout
rate of 35%, this requires recruitment of 77 subjects per
group to meet the anticipated endpoint sample size, for
a total randomized sample of 154 subjects.
Data Safety Monitoring Board (DSMB)
Three times per year, an NIMH-constituted Data and
Safety Monitoring Board (DSMB) reviews the safety data
of participants and the validity and integrity of the col-
lected data. The data reviewed by the DSMB include a
summary of adverse events and abnormal laboratory re-
sults, proposed protocol revisions, and all protocol
deviations.
Discussion
This study of GSK561679 efficacy constitutes the first clin-
ical trial of a CRHR1 antagonist for the treatment of PTSD.
The wealth of preclinical and clinical data implicating both
central CRH-containing circuits and HPA axis dysfunction
in PTSD supports testing of candidate medications that
modulate this system, particularly considering the dearth of
medications demonstrated to be efficacious for PTSD. This
study’s neuropsychological assessments and biological mea-
sures of genotyping, gene expression profiling, fear condi-
tioning and extinction, and dexamethasone suppression
testing will provide valuable insights into the impairments
and pathophysiology of PTSD, even if the GSK561679 doesnot prove superior to placebo in the treatment of PTSD
symptoms. These multimodal variables may also be shown
to have predictive value as biomarkers of PTSD treatment
response.
The NCDDG initiative funding this study includes a
separate project evaluating the effects of GSK561679 on
the neuroendocrine profiles and startle reactivity in fe-
male healthy control subjects (Clinicialtrials.gov identi-
fier: NCT01059227). Upon completion of both protocols
we will explore the datasets to investigate shared and
distinct effects of GSK561679 across the two samples.
Trial status
Recruitment for this trial was on-going at the time this
manuscript was submitted and is expected to continue
through June 2014.
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